Company: ANIX
Filing Date: 2025-09-10
Form Type: 10-Q
Source: 0001493152-25-013000
Chunk: 5

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
 31, 2024 
     32,146,460  
    $321  
    $259,317  
    $(237,867) 
    $-  
    $21,771  
    $(1,080) 
    $20,691 

The
accompanying notes are an integral part of these condensed consolidated financial statements.

3

ANIXA
BIOSCIENCES, INC. AND SUBSIDIARIES

CONDENSED
CONSOLIDATED STATEMENTS OF EQUITY

(in
thousands, except share data)

FOR
THE NINE MONTHS ENDED JULY 31, 2025 (UNAUDITED)

    Common
    Stock  
    Additional  

    Total  
    Non-  

    Shares  
    Par
    Value  
    Paid-in
    Capital  
    Accumulated
     Deficit  
    Treasury
     Stock  
    Shareholders’
     Equity  
    controlling
     Interest  
    Total
    Equity 

    Balance,
    October 31, 2024 
     32,196,862  
    $322  
    $260,432  
    $(240,750) 
    $(6) 
    $19,998  
    $(1,110) 
    $18,888 
  
    Stock
    option compensation to employees and directors 
     -  
     -  
     2,822  
     -  
     -  
     2,822  
     -  
     2,822 
  
    Stock
    options issued to consultants 
     -  
     -  
     77  
     -  
     -  
     77  
     -  
     77 
  
    Common
    stock issued in an at-the-market offering, net of offering expenses of $123 
     611,686  
     6  
     1,918  
     -  
     -  
     1,924  
     -  
     1,924 
  
    Common
    stock issued upon exercise of stock options 
     14,043  
     -  
     2  
     -  
     -  
     2  
     -